App-Quantinova.ai

BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY

D. Van der Heijde - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

bimekizumab

BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY

A. Deodhar - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Non-radiographic axial spondyloarthritis

bimekizumab

BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY

J. F. Merola - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

bimekizumab

BIOMARKERS TO PREDICT RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS

Z. Szekanecz - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Tasocitinib

BREAKTHROUGH INFECTIONS AND PREDICTING SEVERE COVID OUTCOMES DURING RITUXIMAB THERAPY IN AUTOIMMUNE RHEUMATIC DISEASES

M. Y. Md. Yusof - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Rituximab

CAN SINGLE IMPUTATION TECHNIQUES FOR BASDAI COMPONENTS RELIABLY CALCULATE THE COMPOSITE SCORE IN AXIAL SPONDYLOARTHRITIS PATIENTS?

S. Georgiadis - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

CARDIOVASCULAR RISK STRATIFICATION FOR TOFACITINIB PATIENTS IN A LARGE TEACHING HOSPITAL

A. Khatri - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic kidney disease

Tasocitinib

CCL24 SERUM CONCENTRATION CORRELATES WITH DISEASE ACTIVITY AND WORSE PROGNOSIS IN DIFFUSE CUTANEOUS SSc: A PROMISING BIOLOGICAL TARGET TO PREVENT DISEASE PROGRESSION

M. Segal Salto - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Bleomycin

CELL LINEAGE-SPECIFIC TRANSCRIPT DECONVOLUTION OF SYNOVIAL BIOPSIES FROM THE R4RA TRIAL IDENTIFIES CELL POPULATIONS ASSOCIATED WITH RESPONSE TO RITUXIMAB AND TOCILIZUMAB

F. Rivellese - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Tocilizumab

CENTRAL RETINAL ARTERY OCCLUSION (CRAO) LEADING TO BILATERAL BLINDNESS; DUE TO BOTH ARTERITIC AND NON-ARTERITIC ISCHEMIC OPTIC NEUROPATHY

S. Sunari.Subasinghe@gmail.com - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Optic neuropathy

N/A

CHALLENGES IN THE MANAGEMENT OF PSORIATIC ARTHRITIS IN LATIN AMERICA: A SYSTEMATIC REVIEW

A. Ribeiro - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

N/A

CHANGES IN DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH IXEKIZUMAB IN A REAL-WORLD US COHORT

J. Birt - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

LY2439821

CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES

P. M. Machado - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic obstructive pulmonary disease

Glucocorticoid

Characteristics of 4 cases of PL - 7 positive antisynthatase syndrome: interstitial lung disease being a more common feature then myositis

C. Rosa - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Interstitial lung disease

N/A

CHARACTERISTICS OF PAIN IN UK PATIENTS WITH BEHÇET’S SYNDROME: A PROSPECTIVE OBSERVATIONAL COHORT STUDY

K. Plant - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Behcet disease

N/A

CHARACTERIZATION OF HSP60, A STROMAL-DERIVED AUTOANTIGEN, RECOGNIZED BY RA SYNOVIAL RECOMBINANT MONOCLONAL ANTIBODIES

E. Corsiero - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

CHARACTERIZATION OF JOINT DISTRIBUTION AND DISEASE BURDEN IN PATIENTS WITH EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM THE ONGOING FOREMOST STUDY

D. D. Gladman - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Apremilast

CLASSIFYING SELF-REPORTED RHEUMATOID ARTHRITIS FLARES USING DAILY PATIENT-GENERATED DATA

J. Gandrup - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Roxithromycin

CLINICAL CHARACTERISTICS AND BURDEN AMONG PATIENTS WITH SLE AND MUSCULOSKELETAL ORGAN INVOLVEMENT: RESULTS FROM A REAL-WORLD STUDY IN THE US

A. Vadhariya - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

CLINICAL CHARACTERISTICS AND BURDEN AMONG PATIENTS WITH SLE STRATIFIED BY SLEDAI DERIVED SEVERITY: RESULTS FROM A REAL-WORLD STUDY IN THE US

A. Vadhariya - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Filters

45280 Abstracts